Pierre SOUBEYRAN Professeur des universités Université de

!
Pierre SOUBEYRAN
Professeur des universités
Université de Bordeaux
Pierre Soubeyran est Professeur des Universités (Université de Bordeaux) et Médecin
spécialiste des Centres de Lutte contre le Cancer à l’Institut Bergonié à Bordeaux
(Département d’Oncologie Médicale). Il a obtenu son Doctorat en Médecine en 1989,
son Diplôme d’Études Spéciales en 1989 et son Doctorat de Sciences Biologiques et
Médicales (Option : Biologie – Santé) en 1996 suite à ses recherches en hématologie au
MD Anderson Cancer Centre (Houston, USA).
Ses travaux de recherche clinique portent sur les lymphomes non-hodgkiniens et la
prise en charge des cancers des patients âgés. Ses travaux en oncogériatrie visent à
proposer des approches cliniques et sociales adaptées à ces patients âgés.
En 2012, il est Directeur du SIRIC BRIO (Bordeaux Recherche Intégrée Oncologie),
labellisé par l’Institut National du Cancer. Le SIRIC BRIO est porté par l’Institut
Bergonié et regroupe des équipes du CHU, de l’Université de Bordeaux, du CNRS et de
l’INSERM.
Il est également Co-coordonnateur de l’Unité de Coordination en Oncogériatrie
(UCOG), labellisée par l’Institut National du Cancer.
En 2016, il est nommé Directeur de l’Unité INSERM U1218 ACTION (Actions for
Oncogenesis understanding and Target Identification in Oncology).
Depuis mai 2016, il est Directeur de la Recherche de l’Institut Bergonié.
Il est membre de plusieurs sociétés savantes, notamment : American Society of Clinical
Oncology (ASCO), American Society of Hematology (ASH), European Society of Medical
Oncology (ESMO), European Society of Therapeutic Radiology and Oncology (ESTRO),
International Society of Geriatric Oncology (SIOG).
!
!
Principales publications
!
• Mazroui Y, Mathoulin-Pélissier S, Soubeyran P, Rondeau V. General joint frailty models for recurrent event data
with a dependent terminal event: application to follicular lymphoma data. Stat Med 2012;31:1162-76.
• Soubeyran P, Henriques de Figueredo B, Soubeyran I, Mertens C, Cazeau AL. Therapeutic strategies in elderly and
very elderly patients. Best Pract Res Clin Haematol 2012;25:91-100.
• Soubeyran P, Fonck M, Rainfray M, Blanc-Bisson C, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J, Palis R,
Andriamampionona F, Houédé N, Floquet A, Chomy F, Brouste V, Ravaud A, Bellera C, Rainfray M. Predictors of
early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012; 30(15): 1829-
34.
• Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, Soubeyran P. Towards a screening tool
in geriatric oncology: methodological and clinical considerations of the G8 screening tool. Ann Oncol 2012;23:2166-
72.
• Delva F, Soubeyran P, Rainfray M, Mathoulin-Pélissier S. Referral of elderly cancer patients to specialists: action
proposals for general practitioners. Cancer Treat Rev 2012;38:935-41.
• Dupuis J, Riedinger AB, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P,
Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M.
Impact of [18F]Fluorodeoxyglucose PET response evaluation in high-tumor burden follicular lymphoma patients
treated with immuno-chemotherapy (a prospective study from the GELA & GOELAMS). J Clin Oncol 2012;30:4317-
22.
• Mathoulin-Pélissier S, Bellera C, Rainfray M, Soubeyran P. Strategies for determining the best geriatric screening
method for frailty. Lancet Oncol 2013:14:e1-2.
• Allart P, Cousson-Gélie F, Soubeyran P. Are psychosocial factors associated with quality of life in patients with
haematological cancer? A critical review of the literature. PsychoOncology 2013;22:241-9.
• Morschhauser F, Radford J, Van Hoof A, Vitolo U, Rohatiner AZS, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye
A, van Putten WLJ, Kylstra JW, Hagenbeek A for the FIT Investigators. Yttrium-90 ibritumomab tiuxetan
consolidation of first remission in advanced-stage follicular Non-Hodgkin’s lymphoma: updated results after a
median follow-up of 7.3 years from the international, randomized, phase 3 first-line indolent trial in 414 patients.
J Clin Oncol 2013;31:1977-83.
• Bellera C, Praud D, Petit-Monéger A, McKelvie-Sebileau P, Soubeyran P, Mathoulin-Pélissier S. Barriers to
inclusion of older adults in randomised clinical trials on Non-Hodgkin’s lymphoma: a systematic review. Cancer
Treat Rev 2013;39:212-7.

• Soubeyran P. From suboptimal to optimal treatment in older patients with cancer. J Geriatr Oncol 2013, 4: 291-3.
• Hoppe S, Rainfray M, Fonck M, Hoppenreys L, Blanc JF, Ceccaldi J, Mertens C, Blanc-Bisson C, Imbert Y, Cany L,
Vogt L, Dauba J, Houédé N, Bellera C, Floquet A, Fabry MN, Ravaud A, Chakiba C, Mathoulin-Pélissier S, Soubeyran
P. Prognostic factors of functional decline in elderly cancer patients receiving first-line chemotherapy. J Clin
Oncol 2013;31:3877-82
• Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, Albrand G, Servent V, St Jean O, van Pragh I,
Kurtz JE, Périn S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Droz JP, Mathoulin-Pélissier S, Rainfray
M, for the ONCODAGE investigators. Screening for vulnerability in elderly cancer patients: Validation of the G8
screening test. Plos One 2014;9:e115060.
• Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, Lichtman S. Diffuse large B-cell lymphoma in
the elderly : Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An
International Society of Geriatric Oncology Expert Position Paper. J Geriatr Oncol 2015;6:141-52.
• Terret C, Albrand G, Rainfray M, Soubeyran P. Impact of comorbidities on the treatment of non-Hodgkin's
lymphoma: a systematic review. Expert Rev Hematol 2015;8:329-41.
• Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney D, Soubeyran P, Rimsza L,
Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low serum vitamin D levels are associated with inferior
survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol 2015; 33:1482-90.
• Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, Lichtman SM. Approach to therapy of Diffuse
Large B-Cell Lymphoma in the Elderly: The International Society of Geriatric Oncology (SIOG) Expert Position
Commentary. Ann Oncol 2015;26:1058-68.
• Bourdel-Marchasson I, Diallo A, Bellera C, Blanc-Bisson C, Durrieu J, Germain C, Mathoulin-Pélissier S, Soubeyran
P, Rainfray M, Fonck M, Doussau A. One-year mortality in older patients with cancer: development and external
validation of an MNA-based prognostic model. PlosOne 2016;11:e0148523.
• Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, Soubeyran P, Mathoulin-Pelissier S, Tournigand C, Paillaud E,
Laurent M, Audureau E, ELCAPA Study Group. Optimizing the G8 screening tool for older patients with cancer:
diagnostic performance and validation of a six-item version. The Oncologist 2016 Feb;21(2):188-95.
• Petit-Monéger A, Rainfray M, Soubeyran P, Bellera CA, Mathoulin-Pélissier S. Detection of frailty in elderly cancer
patients: improvement of the G8 screening test. J Geriatr Oncol 2016;7:99-107.
• Bron D, Soubeyran P, Fulop T on behalf of the SWG “Aging and Hematology” of the EHA. Innovative approach of
older patients with malignant hemopathies. Haematologica 2016;101:893-5.
• Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier
C,, Offner F, Dupuis J, Caballero D, Canioni D, Marlton P, Delarue R, Zachee P , Seymour J, Salles G, Tilly H. Risk
factors and outcomes of follicular lymphoma patients with histological transformation after response to first-line
immunochemotherapy in the PRIMA study. J Clin Oncol 2016;34:2575-82.
• Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T,
Morschhauser F, Benouaich-Amiel A, Ahle G, Moles MP, Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D,
Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP,
Fabbro M, Naudet F, Hoang-Xuan K, Houot R. Primary CNS Lymphoma at first relapse/progression: characteristics,
management and outcome of 256 patients from the French LOC Network. Neuro-Oncology 2016;18:1297-303.
• Duc S, Rainfray M, Soubeyran P, Fonck M, Blanc JF, Ceccaldi J, Cany L, Brouste V, Mathoulin-Pélissier S. Predictive
factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy. Psycho-Oncology
2016 Feb 23, doi: 10.1002/pon.4090, In Press.
• Soubeyran P, Terret C, Bellera C, Bonnetain F, Saint Jean O, Galvin A, Chakiba C, Zwolakowski MD, Mathoulin-
Pélissier S, Rainfray M. Role of geriatric intervention in the treatment of older patients with cancer: rationale and
design of a phase III multicenter trial. BMC Cancer 2016, In Press.
• Kurtz JE, Soubeyran P, Michallet M, Luporsi E, Albrand H. Biosimilar epoetin for the management of
chemotherapy-induced anemia in elderly patients: a subanalysis of the BiOsimilaRs in the management of anemia
secondary to chemotherapy in HaEmatology and Oncology observational study (ORHEO). Oncotargets and Therapy
2016, In Press.
• Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Henry
Jardel E, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-
Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in
elderly DLBCL patients: a GOELAMS/LYSA phase II prospective trial. The Lancet Haematology 2016, In Press.
• Villar VH, Nguyen TL, Terés S, Bouchecareilh M, Salin B, Bodineau C, Priault M, Soubeyran S, Durán RV. mTORC1
inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation. Nat Comm
2016, In Press.